Saturday 17 October 2026
Export JANX’s income statement to Excel — free account
Janux Therapeutics, Inc.
JANX Healthcare Biotechnology
Janux Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, down 5.55% from fiscal 2024. In the quarter to June 2026, revenue grew 2,238.7%, EPS grew 36.4% and free cash flow grew 150.6%, each against the same quarter a year earlier.
16.49
0.83
−4.79%
Follow JANX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | 0.00 |
+8 more quarters Free account |
P/S ratio |
40.28 | 61.46 | — | 78.40 | |
P/FCF ratio |
0.00 | 0.00 | — | 0.00 | |
P/Operating CF |
77.44 | (70.60) | — | (117.91) | |
P/B ratio |
1.04 | 0.93 | — | 1.55 | |
Price to Tangible BV |
1.04 | 0.93 | — | 1.55 | |
EV/Sales |
(0.17) | (6.02) | — | 27.25 | |
EV/EBITDA |
0.03 | 0.50 | — | 0.00 | |
EV/Operating CF |
0.10 | 1.10 | — | (7.48) | |
EV/FCF |
0.10 | 1.09 | — | (7.38) | |
Quick Ratio |
16.14 | 16.83 | 38.67 | 35.54 | |
Current Ratio |
16.35 | 17.01 | 39.04 | 35.86 | |
Net Debt/EBITDA |
28.46 | 26.30 | 21.26 | 25.12 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.02 | 0.01 | 0.00 | 0.02 | |
Operating CF/Net income |
(0.57) | 0.51 | 0.89 | 0.53 | |
Capex/Depreciation |
0.08 | 0.13 | 0.03 | 0.02 | |
Research and Development Expense of Revenue |
301.88% | 718.27% | 0.00% | 346.29% | |
Selling, General and Administrative Expense of Revenue |
106.78% | 298.23% | 0.00% | 106.22% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
88.26% | 248.30% | 0.00% | 90.44% | |
Graham Net Nets |
0.93 | 1.05 | — | 0.63 | |
Graham Number |
0.00 | 0.00 | — | 0.00 | |
Earnings Yield |
(10.68%) | (13.24%) | — | (6.87%) | |
Free Cash Flow Yield |
(4.34%) | (9.01%) | — | (4.71%) | |
Revenue per Share |
0.16 | 0.06 | 0.00 | 0.16 | |
Operating CF per Share |
0.20 | (0.20) | (0.46) | (0.21) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.20 | (0.20) | (0.46) | (0.21) | |
Cash per Share |
15.43 | 15.26 | 15.60 | 15.95 | |
Shareholders Equity per Share |
14.74 | 15.02 | 15.44 | 15.74 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
14.74 | 15.02 | 15.44 | 15.74 | |
Free Cash Flow |
12.28 | (12.61) | (28.65) | (12.95) | |
Working Capital |
923.19 | 943.13 | 950.89 | 970.26 | |
Capital Expenditures |
(0.20) | (0.27) | (0.11) | (0.09) | |
Net Current Asset Value |
903.67 | 915.36 | 931.14 | 949.88 | |
EV/EBIT |
0.03 | 0.54 | — | 0.00 | |
Capex to Sales |
0.02 | 0.07 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | — | 0.00 | |
| Other line items | |||||
Average Receivables |
0.92 | 18.25 | — | — | |
Average Payables |
3.25 | 2.86 | 4.50 | 2.93 | |
Average Assets |
1,019.93 | 1,039.50 | 1,031.54 | 859.89 | |
Average Common Equity |
959.25 | 977.00 | 989.80 | 816.33 |
Columns are period end dates